Erratum (DOI:10.1016/j.jadohealth.2010.01.010);Human Papillomavirus-Related Disease in Men: Not Just a Women's Issue

Journal of Adolescent Health

Volumn 46, Issue 4 SUPPL., 2010, Pages 614-

  Palefsky, Joel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anal cancer; Human papillomavirus; Penile cancer; Vaccination

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; GENITAL TRACT INFECTION; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; MOUTH CANCER; MOUTH DISEASE; OUTCOME ASSESSMENT; PAPILLOMATOSIS; PENIS CANCER; PENIS DISEASE; POLICY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

EID: 77949460864     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2010.04.001     Document Type: Erratum

References (91)

1. World Health Organization. Viral cancers. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/print.html. Accessed July 29, 2009.
2. American Cancer Society. Cancer facts and figures-2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed July 29, 2009.
3. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 14 (2005) 467-475
4. Ryan D.P., and Mayer R.J. Anal carcinoma: Histology, staging, epidemiology, treatment. Curr Opin Oncol 12 (2000) 345-352
5. Daling J.R., Madeleine M.M., Johnson L.G., et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 116 (2005) 606-616
6. von Krogh G., Lacey C.J.N., Gross G., et al. European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 76 (2000) 162-168
7. Clarke P., Ebel C., Catotti D.N., et al. The psychosocial impact of human papillomavirus infection: Implications for health care providers. Int J STD AIDS 7 (1996) 197-200
8. Munk C., Svare E.I., Poll P., et al. History of genital warts in 10,838 women 20 to 29 years of age from the general population. Risk factors and association with Papanicolaou smear history. Sex Transm Dis 24 (1997) 567-572
9. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 (2003) 1397-1403
10. Woodhall S., Ramsey T., Cai C., et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 84 (2008) 161-166
11. Chin-Hong P.V., Husnik M., Cranston R.D., et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 23 (2009) 1135-1142
12. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al., for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
13. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
14. Harper D.M., Franco E.L., Wheeler C.M., et al., on behalf of the HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 367 (2006) 1247-1255
15. Paavonen J., Jenkins D., Bosch F.X., et al., for the HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial. Lancet 369 (2007) 2161-2170
16. World Health Organization; International Agency for Research on Cancer. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (2007), International Agency for Research on Cancer, Lyon, France 90
17. Gross G., and Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 193 (2004) 35-44
18. Hernandez B.Y., Barnholtz-Sloan J., German R.R., et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 113 suppl 10 (2008) 2883-2891
19. Nielson C.M., Schiaffino M.K., Dunne E.F., et al. Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. J Infect Dis 199 (2009) 7-13
20. Castellsague X., Bosch F.X., Munoz N., et al., for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346 (2002) 1105-1112
21. Baldwin S.B., Wallace D.R., Papenfuss M.R., et al. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 31 (2004) 601-607
22. Bleeker M.C., Heideman D.A., Snijders P.J., et al. Penile cancer: Epidemiology, pathogenesis and prevention. World J Urol 27 (2009) 141-150
23. Giuliano A.R., Lazcano E., Villa L.L., et al. Circumcision and sexual behavior: Factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 124 (2009) 1251-1257
24. Dillner J., von Krogh G., Horenblas S., et al. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 205 (2000) 189-193
25. Madsen B.S., van den Brule A.J., Jensen H.L., et al. Risk factors for squamous cell carcinoma of the penis-Population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 17 (2008) 2683-2691
26. Baldwin S.B., Wallace D.R., Papenfuss M.R., et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 187 (2003) 1064-1070
27. Weaver B.A., Feng Q., Holmes K.K., et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 189 (2004) 677-685
28. Dunne E.F., Nielson C.M., Stone K.M., et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 194 (2006) 1044-1057
29. Giuliano A.R., Lazcano-Ponce E., Villa L.L., et al. The human papillomavirus infection in men study: Human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 17 (2008) 2036-2043
30. Chin-Hong P.V., Vittinghoff E., Cranston R.D., et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: The EXPLORE study. J Infect Dis 190 (2004) 2070-2076
31. Nielson C.M., Flores R., Harris R.B., et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 16 (2007) 1107-1114
32. Svare E.I., Kjaer S.K., Worm A.M., et al. Risk factors for genital HPV DNA in men resemble those found in women: A study of male attendees at a Danish STD clinic. Sex Transm Infect 78 (2002) 215-218
33. Vaccarella S., Franceschi S., Herrero R., et al., IARC HPV Prevalence Surveys Study Group. Sexual behavior, condom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 15 (2006) 326-333
34. Shin H.R., Franceschi S., Vaccarella S., et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 190 (2004) 468-476
35. Castellsague X., Ghaffari A., Daniel R.W., et al. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: A study in Spain and Colombia. J Infect Dis 176 (1997) 353-361
36. Kataoka A., Claesson U., Hansson B.G., et al. Human papillomavirus infection of the male diagnosed by Southern-blot hybridization and polymerase chain reaction: Comparison between urethra samples and penile biopsy samples. J Med Virol 33 (1991) 159-164
37. Giuliano A.R., Lu B., Nielson C.M., et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198 (2008) 827-835
38. Lajous M., Mueller N., Cruz-Valdez A., et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 14 (2005) 1710-1716
39. Bleeker M.C., Hogewoning C.J., Van Den Brule A.J., et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol 47 (2002) 351-357
40. Partridge J.M., Hughes J.P., Feng Q., et al. Genital human papillomavirus infection in men: Incidence and risk factors in a cohort of university students. J Infect Dis 196 (2007) 1128-1136
41. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100 (2008) 407-420
42. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31 (2004) 744-754
43. Jo S., Juhasz A., Zhang K., et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 29 (2009) 1467-1474
44. D'Souza G., Fakhry C., Sugar E.A., et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121 (2007) 143-150
45. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
46. Derkay C.S. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 121 (1995) 1386-1391
47. Derkay C.S. Recurrent respiratory papillomatosis. Laryngoscope 111 (2001) 57-69
48. Johnson L.G., Madeleine M.M., Newcomer L.M., et al. Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973-2000. Cancer 101 (2004) 281-288
49. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. SEER 9 registries (2007), National Cancer Institute, Bethesda, MD
50. Daling J.R., Madeleine M.M., Johnson L.G., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101 (2004) 270-280
51. Bosch F.X., and de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer-Burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
52. Piketty C., Selinger-Leneman H., Grabar S., et al., on behalf of the FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 22 (2008) 1203-1211
53. D'Souza G., Wiley D.J., Li X., et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 48 (2008) 491-499
54. Patel P., Hanson D.L., Sullivan P.S., et al., for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148 (2008) 728-736
55. Frisch M., Biggar R.J., Goedert J.J., and for the AIDS-Cancer Match Registry Study Group. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92 (2000) 1500-1510
56. Daling J.R., Weiss N.S., Klopfenstein L.L., et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 247 (1982) 1988-1990
57. Qualters J.R., Lee N.C., Smith R.A., et al. Breast and cervical cancer surveillance, United States, 1973-1987. MMWR CDC Surveill Summ 41 (1992) 1-15
58. Patel H.S., Silver A.R., and Northover J.M. Anal cancer in renal transplant patients. Int J Colorectal Dis 22 (2007) 1-5
59. Palefsky J.M., Holly E.A., Ralston M.L., et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 177 (1998) 361-367
60. Chin-Hong P.V., Vittinghoff E., Cranston R.D., et al. Age-related prevalence of anal cancer precursors in homosexual men: The EXPLORE study. J Natl Cancer Inst 97 (2005) 896-905
61. Chin-Hong P.V., and Palefsky J.M. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 18 (2005) 67-76
62. Chin-Hong P.V., Berry J.M., Cheng S.C., et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med 149 (2008) 300-306
63. Palefsky J.M., Holly E.A., Ralston M.L., et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: Prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 320-326
64. Palefsky J.M., Holly E.A., Hogeboom C.J., et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 314-319
65. Palefsky J.M., Holly E.A., Efird J.T., et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19 (2005) 1407-1414
66. Watson A.J., Smith B.B., Whitehead M.R., et al. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 76 (2006) 715-717
67. Palefsky J.M., Holly E.A., Ralston M.L., et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 12 (1998) 495-503
68. Palefsky J.M., and Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin N Am 36 (2009) 187-200
69. Heard I., Palefsky J.M., and Kazatchkine M.D. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 9 (2004) 13-22
70. Palefsky J.M., Holly E.A., Ralston M.L., et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183 (2001) 383-391
71. Hernandez B.Y., McDuffie K., Zhu X., et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 14 (2005) 2550-2556
72. Shvetsov Y.B., Hernandez B.Y., McDuffie K., et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: The Hawaii HPV cohort study. Clin Infect Dis 48 (2009) 536-546
73. Goodman M.T., Shvetsov Y.B., McDuffie K., et al. Acquisition of anal human papillomavirus (HPV) infection in women: The Hawaii HPV cohort study. J Infect Dis 197 (2008) 957-966
74. Hessol N.A., Holly E.A., Efird J.T., et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 23 (2009) 59-70
75. von Krogh G., Wikstrom A., Syrjanen K., et al. Anal and penile condylomas in HIV-negative and HIV-positive men: Clinical, histological and virological characteristics correlated to therapeutic outcome. Acta Derm Venereol 75 (1995) 470-474
76. Holly E.A., Whittemore A.S., Aston D.A., et al. Anal cancer incidence: Genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81 (1989) 1726-1731
77. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2006) 2645-2654
78. Hernandez B.Y., Wilkens L.R., Zhu X., et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 14 (2008) 888-894
79. Bleeker M.C., Hogewoning C.J., Berkhof J., et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 41 (2005) 612-620
80. Franceschi S., Castellsague X., Dal Maso L., et al. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer 86 (2002) 705-711
81. Brinton L.A., Reeves W.C., Brenes M.M., et al. The male factor in the etiology of cervical cancer among sexually monogamous women. Int J Cancer 44 (1989) 199-203
82. Bosch F.X., Castellsague X., Munoz N., et al. Male sexual behavior and human papillomavirus DNA: Key risk factors for cervical cancer in Spain. J Natl Cancer Inst 88 (1996) 1060-1067
83. Agarwal S.S., Sehgal A., Sardana S., et al. Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 72 (1993) 1666-1669
84. Muñoz N., Bosch F.X., de Sanjosé S., et al., for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
85. Palefsky J, Giuliano A. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. In: Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress; November 12-15, 2008; France: Nice, Acropolis. Abstract TC 2-11.
86. Giuliano A, Palefsky J. The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. In: Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress; November 12-15, 2008; France: Nice, Acropolis. Abstract SS 19-7a.
87. Petaja T., Keranen H., Karppa T., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 44 (2009) 33-40
88. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
89. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 (2007) 1322-1328
90. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
91. Kim J.J., and Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339 (2009) b3884